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The burden of non-communicable diseases (NCDs) has increased
globally in recent years, particularly in Mexico, and there is a strong
relation between NCDs and the severity and mortality of SARS-CoV-2
infection. However, the separation of health care resources for NCDs
versus infectious disease in Mexico has created a situation where a
syndemic of chronic NCDs and COVID-19 may thrive if not addressed.
The timely and correct management of chronic diseases such as
Diabetes is essential during the COVID-19 pandemic. Several studies
have reported an association between the severity of COVID-19 and
Diabetes, as well as hypertension, cardiovascular disease and
obesity.1–6
Though current evidence does not suggest an increased risk of
COVID-19 infection for those with Diabetes (type 1 and 2 Diabetes),
studies do describe that Diabetes is related to a poor prognosis for
the COVID-19 disease. 3, 5-7
The risk of severe COVID or death in those with Diabetes has been
described since the beginning of the pandemic in Wuhan. However,
prognosis depends on different factors such as age, sex, other
comorbidities like hypertension and obesity, and pro-inflammatory
and pro-coagulative states.7
Aggressive metabolic control in patients with Diabetes and
hypertension can decrease the risk of severe acute respiratory
syndrome due to the COVID-19 virus. Therefore, it is essential to
improve the management of NCDs at all levels of health service
delivery to reduce mortality from COVID.
Objective
This work evaluates the association between Diabetes and 
main comorbidities (Obesity, hypertension and Chronic 
Kidney Disease) on COVID‐19 outcomes (prevalence, 




We used available public data released by the 
Mexican COVID-19 surveillance system from 
January 1 to December 31 of 2020.8  
We assessed hospitalization and fatality risk for 
people with self-reported Diabetes and 
comorbidities, using a multiple logistic regression 
model adjusted for age, sex, smoking status, and 
marginalization of residence.
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Figure 1. Distribution (%) by category of age of people with self-
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RESULTS
Figure 2. Comparison of hospitalization and hospital fatality of COVID-19 disease between 
populations with and without self-reported Diabetes (N= 1,426,094 ).






































Figure 3. Comparison of main COVID-19 related outcomes among people with self-reported 
Obesity, Hypertension, Diabetes and Chronic Kidney Disease (n=1,384,470).
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Diabetes + Hypertension 
+ CKD + Obesity
Diabetes
RESULTS
D: Diabetes   O: Obesity   H: Hypertension   K: Chronic kidney disease




Table 1. Multiple logistic 
regression model for COVID-19 
related outcomes among people 
with self-reported Diabetes and 
Non-Communicable Diseases.
Odds Ratios for main COVID-19 related outcomes among people 
with self-reported Diabetes (N= 3,401,172)
OR    (95%CI)
Positivity 1.31 (1.28-1.33)
Hospitalization 2.20 (2.10-2.30)
In-hospital letality 1.27 (1.27-1.40)
Out of hospital letality 1.98 (1.90-2.10)
Odds Ratios for COVID-19 lethality among people with self-
reported Non-communicable diseases (N=1,384,470)
OR    (95%CI)
Hypertension 1.42 (1.40-1.44)
Obesity 1.73 (1.70-1.76)
Hypertension + Obesity 2.08 (2.03-2.13)
Diabetes 2.26 (2.22-2.30)
Diabetes + Hypertension 2.62 (2.57-2.67)
Diabetes + Obesity 3.12 (3.02-3.22)
Diabetes + Hypertension+ Obesity 3.32 (3.23-3.40)
Obesity +  Chronic Kidney Disease 3.65 (3.09-4.31)
Chronic Kidney Disease 4.50 (4.21-4.82)
Hypertension + Obesity+ Chronic Kidney Disease 6.41 (5.51-7.46)
Diabetes + Chronic Kidney Disease 7.31 (6.55-8.16)
Diabetes + Obesity + Chronic Kidney Disease 8.02 (6.45-9.97)
Diabetes + Hypertension+ Obesity + Chronic Kidney Disease 8.99 (8.20-9.85)
Diabetes + Hypertension+ Chronic Kidney Disease 9.62 (9.11-10.17)
Hypertension +  Chronic Kidney Disease 9.75 (9.08-10.46)
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Multiple logistic regression models, adjusted 
by age, sex and marginalization of the place 
of residence.
CONCLUSION
Of the 3,401,172 people analyzed, Diabetes (DM) was presented in 399,953 (11.8%). In this
population, DM and hypertension (HT) was present in 191,178 (47.8%), DM and Obesity in
35,996 (9.0%), and DM with Chronic Kidney Diseases (CKD) in 27,997 (7.0 %).
When comparing the frequency of hospitalization and death due to COVID-19 between
people with and without DM, it is important to stress that the frequency of hospitalization in
non-diabetics was 190,274 (15.5%), and for death was 80,679 (42.4%); however, these
outcomes had a higher frequency among diabetics, finding a frequency of hospitalization of
95,225 (46.8%), and 45,128 (47.4%) for death.
When analyzing the mortality due to COVID-19 per 100 positive cases according to the
different combinations of comorbidities [Diabetes, Hypertension, Obesity and CKD], the
proportion of deaths for those with DM, HT and CKD was 51.8%; for DM, Obesity and HT
was 18.5%; and for only DM was 18.4%. These results suggest that the presence of
additional comorbidities in patients with DM should be considered of a high risk for death
from COVID-19.
Finally, people with DM had significant (p<.005) higher odds of hospitalization OR:2.2,
hospital 1.27 and non-hospital 1.98 fatality. In addition, people with DM and CKD had the
highest odds of hospitalization 7.3 died in hospital (2.14) or out of hospital (6.5) compared
with cases without DM.
This analysis points out that
Diabetes contributes to the risk of
infection and worse outcomes for
those infected by SARS-CoV-2.
More must be done to prevent
and control Diabetes and
comorbidities to reduce the
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